Skip to main content
Read Gene Spolka Akcyjna logo

Read Gene Spolka Akcyjna — Investor Relations & Filings

Ticker · RDG ISIN · PLRADGN00014 LEI · 2594003D7O7NDUV8GE29 WAR Human health and social work activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-03-23 Regulatory Filings
Country PL Poland
Listing WAR RDG

About Read Gene Spolka Akcyjna

http://www.read-gene.com

Read Gene Spolka Akcyjna is an innovative technology company focused on the commercialization of methods for the detection, prevention, and treatment of various types of cancer. The company specializes in providing genetic tests to identify individual predispositions to neoplastic diseases, enabling precision medicine and early intervention. Its activities encompass clinical trials and chemoprevention, with a particular focus on research into the personalized optimization of microelement levels through dietary modifications and supplements to reduce cancer risk. The company's work is based on a strong scientific foundation and aims to translate genetic research into practical clinical applications.

Recent filings

Filing Released Lang Actions
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Regulatory Filings Classification · 1% confidence The text is a regulatory announcement by the issuer’s management board informing investors that the Polish Patent Office granted the company a patent. It is not a financial report, earnings release, management change, dividend notice, or any other defined category. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-03-23 Polish
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short management announcement describing that the company has been granted a patent by the Polish Patent Office and explaining its technical details and potential impact. It is not a full annual or interim report, audit, earnings release, investor presentation, or governance filing, nor is it a notice of dividends, share issuance, or other specific transaction. There is no designated “patent announcement” category, so by rule it falls into the fallback “Regulatory Filings” category (RNS).
2026-03-23 Polish
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from READ-GENE S.A. regarding the receipt of a patent from the Polish Patent Office. It describes the invention and explains why the company is disclosing this information due to its potential impact on the company's financial and business outlook. Since it is a specific regulatory disclosure of a material event that does not fit into financial reporting, dividend, or governance categories, it falls under the general regulatory filing category.
2026-01-29 Polish
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement from READ-GENE S.A. regarding the receipt of a patent from the Polish Patent Office. It describes the nature of the invention and its potential impact on the company's future prospects. Since it is a specific regulatory announcement regarding company developments that does not fit into financial reporting, dividend, or governance categories, it falls under the general regulatory filing category.
2026-01-05 Polish
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement (942 characters) from the Management Board (Zarząd) of READ-GENE S.A. It reports receiving a decision from the Patent Office of the Republic of Poland granting a patent for an invention related to cancer prognosis. This type of announcement, concerning intellectual property rights (a patent grant), does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). Since it is a specific regulatory/legal event announcement that doesn't match DIRS, LTR, or CAP, the most appropriate fallback category is Regulatory Filings (RNS), as it is a mandatory disclosure of a material event that affects the company's prospects.
2024-03-25 Polish
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board (Zarząd) of READ-GENE S.A. regarding the receipt of a patent grant from the Polish Patent Office (Urząd Patentowy Rzeczypospolitej Polskiej) on March 22, 2024. The patent concerns a method related to selenium concentration as a prognostic marker for malignant melanoma. This type of announcement, detailing the acquisition of intellectual property (a patent), is a significant corporate event that impacts the company's assets and future prospects. It is not a standard financial report (10-K, IR, ER), a management change (MANG), or a dividend notice (DIV). It best fits under general regulatory announcements or potentially a specific category related to corporate assets/IP, but given the provided list, it is a significant corporate disclosure that doesn't fit the highly specific financial/governance codes. Since it is a specific, material announcement that isn't covered by the other codes (like M&A, Financing, or Director Dealing), it falls best into the general regulatory/miscellaneous category, RNS, or potentially LTR if it were a legal dispute, but here it is a positive legal/IP event. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a material, non-standard disclosure like a patent grant announcement.
2024-03-25 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.